4//SEC Filing
Katabi Maha 4
Accession 0001104659-24-038589
CIK 0001831828other
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 9:46 PM ET
Size
17.6 KB
Accession
0001104659-24-038589
Insider Transaction Report
Form 4
Katabi Maha
Director
Transactions
- Sale
Class A Common Stock
2024-03-21$45.52/sh−12,617$574,326→ 3,561,155 total(indirect: By Sofinnova Venture Partners X, L.P.) - Sale
Class A Common Stock
2024-03-25$40.50/sh−340,000$13,770,000→ 2,793,987 total(indirect: By Sofinnova Venture Partners X, L.P.) - Sale
Class A Common Stock
2024-03-21$43.00/sh−32,756$1,408,508→ 3,595,690 total(indirect: By Sofinnova Venture Partners X, L.P.) - Sale
Class A Common Stock
2024-03-21$44.00/sh−21,918$964,392→ 3,573,772 total(indirect: By Sofinnova Venture Partners X, L.P.) - Sale
Class A Common Stock
2024-03-21$46.18/sh−13,718$633,497→ 3,547,437 total(indirect: By Sofinnova Venture Partners X, L.P.) - Sale
Class A Common Stock
2024-03-22$40.51/sh−413,450$16,748,860→ 3,133,987 total(indirect: By Sofinnova Venture Partners X, L.P.)
Footnotes (7)
- [F1]A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the "Purchase") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. ("SVP X"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The shares are held directly by SVP X. Sofinnova Management X, L.P. ("SM X LP") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. ("SM X LLC") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.06 to $45.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $41.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $41.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4.
Documents
Issuer
Vera Therapeutics, Inc.
CIK 0001831828
Entity typeother
Related Parties
1- filerCIK 0001720685
Filing Metadata
- Form type
- 4
- Filed
- Mar 24, 8:00 PM ET
- Accepted
- Mar 25, 9:46 PM ET
- Size
- 17.6 KB